Good morning :)
$
₹
Lyell Immunopharma Inc

Lyell Immunopharma Inc

LYEL

NASDAQ
Asset Logo

Lyell Immunopharma Inc

LYEL

NASDAQ
$15.4443.38% (+4.67)
$
₹
$15.4443.38% (+4.67)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $266.6M the stock is ranked 3932

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.15
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-12.86
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 8 analysts reports

Buy
7 analysts
Hold
0 analyst
Sell
1 analyst

Price Upside

+145.46%

Earnings Growth

+57.55%

Rev. Growth

-67%

See Detailed Forecast

Company Profile

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 145.46% growth, versus a trailing 3-year CAGR of -29.48%.

2026
Current$15.43Baseline
Analyst Target - 1 year
Target$37.88+145.46%

All values in $

202220232024202520262027$27.73$43.93$60.14Target+145.46%
2026
Current$15.43Baseline
Analyst Target - 1 year
Target$37.88+145.46%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -67.00% growth, versus a trailing 3-year CAGR of -92.48%.

2025
Current$0.03Baseline
Forecast for Dec 2026
High$0.04+27.78%
Average$0.01-67%
Low$0-100%

All values in $ Million

20212022202320242025202610.6584.680.130.060.03Low-100%Average-67%High+27.78%
2025
Current$0.03Baseline
Forecast for Dec 2026
High$0.04+27.78%
Average$0.01-67%
Low$0-100%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-16.3Baseline
Forecast for Dec 2026
High$-6.92+57.55%
Average$-6.92+57.55%
Low$-6.92+57.55%

All values in $

202120222023202420252026-22-8.49-14.14-7.68-16.3Low+57.55%Average+57.55%High+57.55%
2025
Current$-16.3Baseline
Forecast for Dec 2026
High$-6.92+57.55%
Average$-6.92+57.55%
Low$-6.92+57.55%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0
-38.8
0
-140.7
0
-24.1
0
-44.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00.010.030.01000.01000
Net Income-60.66-45.80-44.58-191.93-52.19-42.68-38.84-140.72-24.15-44.75
Net Profit Margin-2022233.33%-352376.92%-131126.47%-1744863.63%-745642.85%-533550%-258973.33%-2345383.33%-1207650%-1118875%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Lyell Immunopharma Inc -1.15-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare LYEL with any stock or ETF
Compare LYEL with any stock or ETF
Comparing from
LYEL
ABBV
AMGN
Loading...

Frequently asked questions

  1. Lyell Immunopharma Inc (LYEL) share price today is $15.44 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $16.64 and a day low of $13.49.

  2. Lyell Immunopharma Inc stock trades on NASDAQ under the ticker symbol LYEL.

  3. Lyell Immunopharma Inc's market capitalization is $266.61M as of November 5, 2026 at 2:29 AM IST.

  4. Lyell Immunopharma Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Lyell Immunopharma Inc's price-to-book (P/B) ratio is 1.15 as of November 4, 2026.

  6. Yes, You can buy Lyell Immunopharma Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Lyell Immunopharma Inc shares in three steps: 1. Search Lyell Immunopharma Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Lyell Immunopharma Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Lyell Immunopharma Inc (LYEL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.6475 shares at the current price of $15.44.

Loading...